HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury (TBI) Registry Coalition (“Coalition”). This esteemed coalition represents a unified alliance of both private sector entities and non-profit organizations committed to fostering the development of a national TBI registry.
The Coalition is dedicated to advancing research, raising public awareness, and supporting clinical trials that address traumatic brain injuries, which affect millions each year. By joining the Coalition, Nexalin America underscores its commitment to improving outcomes for TBI patients and enhancing public understanding of this critical health issue.
Other notable members of the Coalition include the NFL Players Association, Spaulding Rehabilitation at Mass General, the United States Brain Injury Alliance, Abbott, and the American Academy of Neurology. This group of diverse partners leverages a wealth of knowledge and resources to drive progress in the treatment and management of brain injuries.
As a new member, Nexalin America will play an important role among the private sector partners in the Coalition. The company plans to contribute its background and expertise in neurostimulation technology to support the Coalition’s objectives, including the pivotal development of a comprehensive national TBI registry.
Mark White, CEO of Nexalin, stated, “This partnership with the National TBI Registry Coalition represents a significant step forward in our mission to combat brain injuries through advanced technology and collaborative research. We are excited to work alongside such distinguished organizations and contribute to a cause that has the potential to change lives dramatically.”
“We are delighted to have Nexalin as part of the NTRC and excited to see the diversity of companies and organizations joining together to advocate for the creation of a national registry for individuals living with TBI,” said Julie Pawelczyk, Executive Director of the Coalition.
The inclusion of Nexalin America in the Coalition not only enhances the group's capabilities but also signals a growing acknowledgment of the crucial role that innovative technologies can play in understanding and treating traumatic brain injuries.
The Nexalin America division was established in 2023 with a goal of fostering relationships within the U.S. Department of Defense, U.S. Department of Veterans Affairs, U.S. Department of Health and Human Services, and other private and public entities.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device was recently approved in Oman and China. Additional information about the Company is available at: https://nexalin.com.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
RedChip Companies Inc.
Dave Gentry
407-644-4256
or 407-491-4498
nxl@redchip.com
